Cargando…

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

CONTEXT: The stepwise hyperglycemic clamp procedure (SHCP) is the gold standard for measuring the renal threshold for glucose excretion (RT(G)), but its use is limited to small studies in specialized laboratories. OBJECTIVE: The objective of the study was to validate a new method for determining RT(...

Descripción completa

Detalles Bibliográficos
Autores principales: Polidori, David, Sha, Sue, Ghosh, Atalanta, Plum-Mörschel, Leona, Heise, Tim, Rothenberg, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706739/
https://www.ncbi.nlm.nih.gov/pubmed/23585665
http://dx.doi.org/10.1210/jc.2012-4205
_version_ 1782276395149295616
author Polidori, David
Sha, Sue
Ghosh, Atalanta
Plum-Mörschel, Leona
Heise, Tim
Rothenberg, Paul
author_facet Polidori, David
Sha, Sue
Ghosh, Atalanta
Plum-Mörschel, Leona
Heise, Tim
Rothenberg, Paul
author_sort Polidori, David
collection PubMed
description CONTEXT: The stepwise hyperglycemic clamp procedure (SHCP) is the gold standard for measuring the renal threshold for glucose excretion (RT(G)), but its use is limited to small studies in specialized laboratories. OBJECTIVE: The objective of the study was to validate a new method for determining RT(G) using data obtained during a mixed-meal tolerance test (MMTT) in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus (T2DM). DESIGN: This was an open-label study with 2 sequential parts. SETTING: The study was performed at a single center in Germany. PATIENTS: Twenty-eight subjects with T2DM were studied. INTERVENTIONS: No treatment intervention was given in part 1. In part 2, subjects were treated with canagliflozin 100 mg/d for 8 days. In each part, subjects underwent an MMTT and a 5-step SHCP on consecutive days. MAIN OUTCOME MEASURES: For both methods, RT(G) was estimated using measured blood glucose (BG) and urinary glucose excretion (UGE); estimated glomerular filtration rates were also used to determine RT(G) during the MMTT. The methods were compared using the concordance correlation coefficient and geometric mean ratios. RESULTS: In untreated and canagliflozin-treated subjects, the relationship between UGE rate and BG was well described by a threshold relationship. Good agreement was obtained between the MMTT-based and SHCP-derived RT(G) values. The concordance correlation coefficient (for all subjects) was 0.94; geometric mean ratios (90% confidence intervals) for RT(G) values (MMTT/SHCP) were 0.93 (0.89–0.96) in untreated subjects and 1.03 (0.78–1.37) in canagliflozin-treated subjects. Study procedures and treatments were generally well tolerated in untreated and canagliflozin-treated subjects. CONCLUSIONS: In both untreated and canagliflozin-treated subjects with T2DM, RT(G) can be accurately estimated from measured BG, UGE, and estimated glomerular filtration rates using an MMTT-based method.
format Online
Article
Text
id pubmed-3706739
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-37067392013-07-24 Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus Polidori, David Sha, Sue Ghosh, Atalanta Plum-Mörschel, Leona Heise, Tim Rothenberg, Paul J Clin Endocrinol Metab JCEM Online: Brief Reports CONTEXT: The stepwise hyperglycemic clamp procedure (SHCP) is the gold standard for measuring the renal threshold for glucose excretion (RT(G)), but its use is limited to small studies in specialized laboratories. OBJECTIVE: The objective of the study was to validate a new method for determining RT(G) using data obtained during a mixed-meal tolerance test (MMTT) in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus (T2DM). DESIGN: This was an open-label study with 2 sequential parts. SETTING: The study was performed at a single center in Germany. PATIENTS: Twenty-eight subjects with T2DM were studied. INTERVENTIONS: No treatment intervention was given in part 1. In part 2, subjects were treated with canagliflozin 100 mg/d for 8 days. In each part, subjects underwent an MMTT and a 5-step SHCP on consecutive days. MAIN OUTCOME MEASURES: For both methods, RT(G) was estimated using measured blood glucose (BG) and urinary glucose excretion (UGE); estimated glomerular filtration rates were also used to determine RT(G) during the MMTT. The methods were compared using the concordance correlation coefficient and geometric mean ratios. RESULTS: In untreated and canagliflozin-treated subjects, the relationship between UGE rate and BG was well described by a threshold relationship. Good agreement was obtained between the MMTT-based and SHCP-derived RT(G) values. The concordance correlation coefficient (for all subjects) was 0.94; geometric mean ratios (90% confidence intervals) for RT(G) values (MMTT/SHCP) were 0.93 (0.89–0.96) in untreated subjects and 1.03 (0.78–1.37) in canagliflozin-treated subjects. Study procedures and treatments were generally well tolerated in untreated and canagliflozin-treated subjects. CONCLUSIONS: In both untreated and canagliflozin-treated subjects with T2DM, RT(G) can be accurately estimated from measured BG, UGE, and estimated glomerular filtration rates using an MMTT-based method. Endocrine Society 2013-05 2013-04-12 /pmc/articles/PMC3706739/ /pubmed/23585665 http://dx.doi.org/10.1210/jc.2012-4205 Text en Copyright © 2013 by The Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle JCEM Online: Brief Reports
Polidori, David
Sha, Sue
Ghosh, Atalanta
Plum-Mörschel, Leona
Heise, Tim
Rothenberg, Paul
Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
title Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
title_full Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
title_fullStr Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
title_full_unstemmed Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
title_short Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
title_sort validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus
topic JCEM Online: Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706739/
https://www.ncbi.nlm.nih.gov/pubmed/23585665
http://dx.doi.org/10.1210/jc.2012-4205
work_keys_str_mv AT polidoridavid validationofanovelmethodfordeterminingtherenalthresholdforglucoseexcretioninuntreatedandcanagliflozintreatedsubjectswithtype2diabetesmellitus
AT shasue validationofanovelmethodfordeterminingtherenalthresholdforglucoseexcretioninuntreatedandcanagliflozintreatedsubjectswithtype2diabetesmellitus
AT ghoshatalanta validationofanovelmethodfordeterminingtherenalthresholdforglucoseexcretioninuntreatedandcanagliflozintreatedsubjectswithtype2diabetesmellitus
AT plummorschelleona validationofanovelmethodfordeterminingtherenalthresholdforglucoseexcretioninuntreatedandcanagliflozintreatedsubjectswithtype2diabetesmellitus
AT heisetim validationofanovelmethodfordeterminingtherenalthresholdforglucoseexcretioninuntreatedandcanagliflozintreatedsubjectswithtype2diabetesmellitus
AT rothenbergpaul validationofanovelmethodfordeterminingtherenalthresholdforglucoseexcretioninuntreatedandcanagliflozintreatedsubjectswithtype2diabetesmellitus